| 2006 |
|
|
The company was founded at the Karolinska Institute by Peter Wolpert and Marie Moberg.
Acquisition of a patent and project portfolio based on research since the end of the 1980s by the Swedish dermatologist Dr Sven Moberg at Sahlgrenska University Hospital.
|
|
|
| 2007 |
|
|
Clinical Phase II results for Kaprolac® Scalp Solution for treatment of seborrhoeic eczema.
Financing of SEK 28m. |
|
|
| 2008 |
|
|
Clinical Phase III results for Emtrix® in 493 patients.
Clinical Phase III trial regarding Kaprolac® Scalp Solution.
Acquisition of all assets from the bankruptcy estate of Zelmic Technologies AB, including the pharmaceutical projects A-Fizz™ and Limtop, patent applications and laboratory equipment.
Financing of SEK 40m.
Licence agreement with MedPharm Ltd on access to a patent‑protected formulation technology. |
|
|
| 2009 |
|
|
Distribution agreement on sales of the company's nail preparation Emtrix® in the Nordic countries with Antula Healthcare AB.
Clinical Phase I/II results for atopic eczema.
Patent application for MOB-015.
SEK 4.2m in grants from Vinnova (Swedish Governmental Agency for Innovation Systems) for development of MOB-015.
Registration of three cosmetic products in the Kaprolac® series with the Swedish Medical Products Agency.
Financing of SEK 40m from both existing and new owners. |
|
|
| 2010 |
|
|
Marketing authorization (CE mark) in Europe for Emtrix®.
Marketing authorization (CE mark) in Europe for Kaprolac® Scalp Solution.
Loan facility of SEK 50m with Shejk M. Al-Amoudi. Distribution agreement for Emtrix® on a number of markets.
Launch of Emtrix® starting in Sweden, Denmark, Norway and Finland.
Application for clinical Phase II trial for MOB-015. |
| 2011 |
|
|
Launch of Emtrix® in the United States, Canada, Portugal and Switzerland.
Listing on NASDAQ OMX Stockholm, main list.
Financing of SEK 86m from both existing and new owners.
Clinical phase II trial regarding MOB-015 in 237 patients.
Marketing authorization (CE mark) in Europe for Kaprolac® Skin Repair and Hydration.
Several distribution agreements for Emtrix®, including a distribution agreement with Meda for a number of major European markets.
|
| 2012 |
|
|
Moberg Pharma and Pharmaplan sign distribution agreement for Nalox™/Emtrix® in South Africa.
Start of phase II clinical trial for Limtop.
Distribution agreement for Nalox™/Emtrix® in Iran.
Walmart doubles the distribution of Kerasal® Nail in the U.S.
Establishment of own market presence in the U.S. through the acquisition of Moberg Pharma North America (former Alterna LLC).
|